Search Job Title Only
News By Subject
News by Disease
News By Date
Get Our FREE
) Completes Sale of Diagnostics Business to
2/1/2011 8:41:52 AM
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genzyme Corporation (Nasdaq: GENZ) today announced that it has completed the sale of its diagnostic products business to Sekisui Chemical Co., Ltd. for $265 million in cash.
(SASY.PA) Agree on Deal - In Principle
Alexion Pharmaceuticals Inc.
for $111 Million and Creates Translational Medicine Group to Accelerate Development of Expanded Portfolio
(GENZ) Bid To February 15
"Artificial Pancreas" Shows Promise in Pregnancy,
(GENZ) CEO Says Proxy Fight Not Likely
Study: Device Recalls In Europe, U.S. Occur At Similar Rates No Safety Benefit from Slower, More Burdensome
Operations For $265 Million
(GB) to Build New Facility in Fort Wayne, Will Create Up to 76 jobs by 2014
American Diagnostica Inc.
to Enter the U.S. Diagnostic Drug Market
Chairman, President and CEO Upon Resignation of
comments powered by Disqus.
comments powered by
Biotech/Pharma - Mergers and Acquisitions
Medical Dev. & Diag. - Mergers and Acquisitions